SOSAFE-GMBH
7.2.2024 09:01:27 CET | Business Wire | Press release
SoSafe, Europe’s leading vendor for security awareness, behavior, and culture change, today announced the appointment of Andrew Rose as its new Chief Security Officer (CSO). With a wealth of experience in the industry, Rose is a highly accomplished cyber security executive with a strong focus on the people-centric aspects of cyber security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240207094549/en/
Andrew Rose appointed as new Chief Security Officer at leading security awareness vendor SoSafe (Photo: Business Wire)
In his role as CSO, Rose will focus on driving SoSafe’s vision to strengthen digital self-defense worldwide and help customers transform their security culture. He’ll also bring hands-on experience, knowledge, and perspective in managing risk and improving cyber security posture across complex enterprises.
Recognized for his outstanding contributions to the field, Rose was awarded the prestigious title of 'European CISO of the Year 2018' at the SC Awards, and has been a part of the CSO30 every year since its inception in 2020. Across his career, Rose has transformed security management for multiple major organizations in the legal, aviation, technology, and finance sectors.
Notably, Rose held the position as Resident CISO at Proofpoint Inc., where he helped customers enhance their security practices, cultivated a community of CISOs and represented the brand externally. Prior to that, he oversaw the cyber security of UK airspace traffic at NATS and managed the secure processing of trillions of pounds in transfers at Vocalink, a Mastercard company. He also worked at Forrester Research, where he was Principal Analyst covering the awareness and culture change space and developed influential models for the security awareness industry. In 2015, when Rose implemented the models he had designed at Forrester, he was awarded ‘UK Awareness Campaign of the Year’ at the UK Cyber Security Awards. Rose also has an established record in the legal sector with over a decade as CISO at 'magic circle' firms Clifford Chance LLP and Allen & Overy LLP.
Niklas Hellemann, Psychologist and CEO of SoSafe, remarked: "Andrew’s expertise is a perfect match for our mission at SoSafe. In an era where AI-powered cyber threats are escalating, Andrew's extensive industry experience is invaluable in leading our efforts to be the global industry leader in fortifying the human aspect of cyber security.”
Rose's decision to join SoSafe was driven by the company's unwavering focus on addressing the critical problem of the underestimated human factor in cyber security. “There is a huge imbalance in focus as the biggest part of security budgets are dedicated to security technology while according to the World Economic Forum, 95% of cyber threats have a human element involved. SoSafe’s commitment to strengthening the human factor, coupled with their innovative use of behavioral science and technology, aligns perfectly with my vision.”
“SoSafe’s approach to security awareness is unique in the industry: Having a CEO with a background in psychology means that the human-centric perspective is deeply rooted in their DNA. They focus on behavioral science to tackle the problem and then use technology to enable the solution”, Rose stated.
By joining SoSafe, Andrew Rose will further strengthen the company's position as a leader in the industry. With his track record of success and commitment to driving secure behavior in organizations, Andrew Rose is poised to make a significant contribution to the company's ongoing mission of strengthening digital self-defense.
About SoSafe
SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by Dr Niklas Hellemann, Lukas Schaefer, and Felix Schuerholz. Today, it serves more than 4500 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team consists of more than 370 employees at seven locations: Cologne (headquarters), Amsterdam, Berlin, Lisbon, London, Munich, and Paris.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207094549/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
